LB Pharmaceuticals Inc (LBRX)
NASDAQ: LBRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LBRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.26B
- EPS (TTM)
- -$1.12
- Dividend yield
- None
- 52-week range
- 15.55 – 50.16
- Day range
- 38.57 – 40.67
- Volume / Avg
- 302.94K / 373.16K
- Beta
- —
- Shares outstanding
- 32.36M
52-week range
LBRX stock today
On Nov 20, LBRX ended the session at $38.85, shedding $1.19 (2.97%), versus the S&P 500's 3.70% decline. At this level, LBRX sits in the middle of its 52-week range of $15.55 to $50.16: 22.5% below the high, set on Aug 25, 2026 and 149.8% above the low. LBRX is up 74.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 153.4%.
LB Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.12), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About LB Pharmaceuticals
Company profileLB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Heather D. Turner Esq., J.D.
- Headquarters
- New York, NY
- Employees
- 62
- IPO year
- 2025
- Website
- lbpharma.us
Financial highlights
Full financialsLB Pharmaceuticals reported a net loss of $25.2 million, compared with a loss of $63.1 million a year earlier. Diluted earnings per share came in at -$3.13.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | — | — |
| Growth | — | — |
| Net income | $-25.20M | $-63.10M |
| EPS (diluted) | $-3.13 | $-176.15 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$58.00+49.29%
- Strong buy 2
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-1.79 vs $-1.61
- Surprise
- -11.18%
LBRX news
All LBRX news- Guggenheim names LB Pharmaceuticals a top idea ahead of pivotal trial dataInvesting.com
- LB Pharmaceuticals to Participate in Upcoming Investor EventsGlobeNewswire
- LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP CongressGlobeNewswire
- LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
LB Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AVLNAvalyn Pharma Inc. | 28.40 | -1.05% | $1.26B | vs LBRX |
| MNKDMannKind Corporation | 3.85 | -2.53% | $1.24B | vs LBRX |
| SLNSilence Therapeutics Plc American Depository Share | 19.81 | 0.00% | $1.23B | vs LBRX |
| GENBGenerate Biomedicines Inc. | 9.54 | -8.00% | $1.23B | vs LBRX |
| OCULOcular Therapeutix Inc. | 5.57 | -4.95% | $1.23B | vs LBRX |
| MLYSMineralys Therapeutics Inc. | 13.66 | -3.53% | $1.21B | vs LBRX |
| INVAInnoviva Inc. | 18.41 | 0.00% | $1.31B | vs LBRX |
| AMPHAmphastar Pharmaceuticals Inc. | 28.25 | +0.50% | $1.20B | vs LBRX |
Indexes, lists and sector
LB Pharmaceuticals stock FAQ
What is LB Pharmaceuticals's stock price today?
LBRX last traded at $38.85 as of Nov 20, 4:00 PM EST, down 2.97% on the day. Prices are delayed at least 15 minutes.
Who is LB Pharmaceuticals's CEO?
Ms. Heather D. Turner Esq., J.D. is the chief executive officer of LB Pharmaceuticals Inc, which has about 62 employees.
What is the LBRX 52-week high?
The 52-week high for LBRX is $50.16 and the 52-week low is $15.55. The stock is currently 22.5% below its high.